Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Flunarizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 4/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 1.00 |
| ▸ | GAA known ✓ | P10253 | 3/20 | 1.00 |
| ▸ | OPRD1 known ✓ | P41143 | 2/20 | 1.00 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.97 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.97 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.97 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.97 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flunarizine SCHEMBL1321708 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2AHIF1AOPRM1 | |
| Flunarizine SCHEMBL120168 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2AHIF1AOPRM1 | |
| Flunarizine SCHEMBL1009444 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2AHIF1AOPRM1 | |
| Flunarizine SCHEMBL16226917 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2AHIF1AOPRM1 | |
| Hydrochloric Acid SCHEMBL11201247 | 0.99 | LMNA (0.97) | LMNAMEN1KMT2AHIF1AOPRM1 | |
| Flunarizine SCHEMBL43440 | 0.99 | LMNA (1.00) | LMNAMEN1KMT2AHIF1AOPRM1 | |
| Flunarizine SCHEMBL16225927 | 0.99 | LMNA (1.00) | LMNAMEN1KMT2AHIF1AOPRM1 | |
| Flunarizine SCHEMBL43441 | 0.99 | LMNA (1.00) | LMNAMEN1KMT2AHIF1AOPRM1 | |
| SCHEMBL2615158 | 0.97 | LMNA (0.97) | LMNAMEN1KMT2AHIF1AOPRM1 | |
| SCHEMBL2615163 | 0.97 | LMNA (0.97) | LMNAMEN1KMT2AHIF1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 928 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-222624364-U | Flunarizine hydrochloride capsule raw material heating device | 山西晋商药业集团晋广医药有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-117064863-B | Preparation method of flunarizine hydrochloride capsules | 贵州缔谊健康制药有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-118662583-A | Composition for preventing and treating encephalatrophy and preparation method thereof | 情志健康管理(上海)有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-118593576-A | Composite medicine for treating migraine | 赵雪杉 | 2024-09-06 | — | — | CN | claimed |
| CN-118021984-A | Compound external preparation, preparation method and application thereof | 南方医科大学 | 2024-05-14 | — | — | CN | claimed |
| CN-116747206-B | Flunarizine hydrochloride capsule and preparation method thereof | 广东彼迪药业有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-117462481-A | Promoter for promoting nasal delivery of pharmaceutical ingredients and application thereof | 南京星叶生物科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-117064863-A | Preparation method of flunarizine hydrochloride capsules | 贵州缔谊健康制药有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-117045654-A | Application of flunarizine hydrochloride in preparation of extreme environment hypoxia medicament | 中国人民解放军陆军军医大学 | 2023-11-14 | — | — | CN | claimed |
| CN-117030867-A | Method for detecting various genotoxic impurities in flunarizine hydrochloride capsules | 石家庄市华新药业有限责任公司 | 2023-11-10 | — | — | CN | claimed |
| CN-1383825-A | Flunarizine hydrochloride injection and its prepn process | CAO CHANGCHENG (CN) | 2002-12-11 | — | — | CN | claimed |
| JP-2001519394-A | — | — | 2001-10-23 | — | — | JP | claimed |
| US-20010011098-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-08-02 | — | — | US | claimed |
| US-20010004640-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-06-21 | — | — | US | claimed |
| EP-1021184-A1 | USE OF FLUNARIZINE FOR THE TOPICAL TREATMENT OF GLAUCOMA | LABORATOIRE MEDIDOM S.A. (CH) | 2000-07-26 | — | — | EP | claimed |
| WO-1999018963-A1 | USE OF FLUNARIZINE FOR THE TOPICAL TREATMENT OF GLAUCOMA | LABORATOIRE MEDIDOM S.A. (CH) | 1999-04-22 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| CN-1109326-A | Fuguiqin hydrochloride injection | ZHECHUAN PHARMACEUTICAL FACTOR (CN) | 1995-10-04 | — | — | CN | claimed |
| CN-1109333-A | Composite fuguiqin hydrochloride capsule | ZHECHUAN PHARMACEUTICAL FACTOR (CN) | 1995-10-04 | — | — | CN | claimed |
| EP-0628313-A1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with dinretics or calcium antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011098-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | AGTR1, REN, AGTR2 | OPRM1 52/4885OPRK1 186/4885GAA 1459/4885 |
| US-20010004640-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | AGTR1, REN, AGTR2 | OPRM1 52/4885OPRK1 186/4885GAA 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.